Supplemental material
OncoImmunology
Volume 7, 2018 - Issue 8
Original Research
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
, 
, , , , , , , , & show all
Adina HughesBioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdomhttp://orcid.org/0000-0002-5711-627X
http://orcid.org/0000-0002-5711-627X, Molly A. TaylorBioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdomhttp://orcid.org/0000-0002-7885-8395
http://orcid.org/0000-0002-7885-8395, , , , , , , Larissa S. CarnevalliBioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United KingdomCorrespondence[email protected]
http://orcid.org/0000-0001-7432-0195
http://orcid.org/0000-0001-7432-0195 & Charles SinclairBioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United KingdomCorrespondence[email protected]
http://orcid.org/0000-0001-6857-9993
http://orcid.org/0000-0001-6857-9993 show all